$20M placement and SPP, convertible notes amended
Filed with ASX · · 19 pages · English
In the deck
Story so far
Earlier from Imugene
- 100% and 80% ORRs in Subset Indications in azer-cel study
- Trading Halt
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- FDA Supports Strategy Toward Registration for Azer-cel
Later from Imugene
- Prospectus
- Diamond Equity Research Releases Update Note on Imugene Limited (ASX: IMU)
- Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract
- First Patient in BTKi Combination Cohort of azer-cel study
- Azer-cel Granted FDA Fast Track Designation for CLL and MZL
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene